Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shMetadherin
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intra-arterial, Intrathecal, Intraperitoneal, Ophthalmic, Intravitreal, Inhalation, Parenteral
01
Overview
shMetadherin is a short hairpin RNA (shRNA) construct designed to silence the expression of the Metadherin (MTDH) gene, also known as Astrocyte Elevated Gene-1 (AEG-1). Metadherin is a well-characterized oncoprotein that promotes tumor progression, metastasis, and chemoresistance in various cancers, including breast cancer. By utilizing the RNA interference (RNAi) pathway, shMetadherin mediates the sequence-specific degradation of MTDH mRNA, resulting in a significant reduction of MTDH protein levels. This knockdown inhibits downstream oncogenic signaling pathways such as PI3K/Akt, NF-κB, and Wnt/β-catenin, leading to decreased cell proliferation, migration, and invasion. In the context of breast cancer research, shMetadherin is frequently employed as a tool to investigate the role of MTDH in the tumor immune microenvironment and to validate MTDH as a potential therapeutic target.
- Other names
- sh-MTDHshRNA-MTDHMetadherin shRNA
02
Targets
MTDH (Metadherin)
Beyond the preview
Go deeper on shMetadherin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shMetadherin.